Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.03M Sell
5,766
-642
-10% -$229K 0.21% 94
2025
Q4
$2.1M Buy
6,408
+2,372
+59% +$752K 0.19% 91
2025
Q3
$1.14M Buy
4,036
+1,419
+54% +$412K 0.11% 124
2025
Q2
$731K Buy
2,617
+13
+0.5% +$3.68K 0.08% 133
2025
Q1
$811K Sell
2,604
-1,500
-37% -$443K 0.09% 129
2024
Q4
$1.07M Buy
4,104
+2,218
+118% +$658K 0.11% 119
2024
Q3
$608K Sell
1,886
-25
-1% -$8.18K 0.07% 140
2024
Q2
$597K Buy
1,911
+136
+8% +$40K 0.07% 142
2024
Q1
$505K Buy
1,775
+44
+3% +$12.9K 0.06% 145
2023
Q4
$498K Sell
1,731
-5,219
-75% -$1.42M 0.07% 142
2023
Q3
$1.87M Buy
6,950
+1,345
+24% +$336K 0.22% 87
2023
Q2
$1.24M Sell
5,605
-726
-11% -$168K 0.14% 112
2023
Q1
$1.53M Sell
6,331
-1,148
-15% -$282K 0.19% 91
2022
Q4
$1.96M Buy
7,479
+1,148
+18% +$308K 0.25% 74
2022
Q3
$1.43M Sell
6,331
-6
-0.1% -$1.45K 0.2% 87
2022
Q2
$1.54M Buy
6,337
+583
+10% +$143K 0.21% 86
2022
Q1
$1.39M Buy
5,754
+1,946
+51% +$447K 0.18% 85
2021
Q4
$857K Buy
3,808
+1,534
+67% +$324K 0.11% 116
2021
Q3
$484K Buy
2,274
+116
+5% +$26.7K 0.07% 148
2021
Q2
$526K Buy
2,158
+43
+2% +$10.6K 0.07% 137
2021
Q1
$551K Buy
2,115
+36
+2% +$8.59K 0.09% 128
2020
Q4
$478K Sell
2,079
-67
-3% -$15.4K 0.09% 114
2020
Q3
$545K Sell
2,146
-546
-20% -$135K 0.12% 101
2020
Q2
$635K Buy
2,692
+128
+5% +$29.2K 0.16% 93
2020
Q1
$520K Buy
2,564
+828
+48% +$181K 0.14% 93
2019
Q4
$419K Buy
+1,736
New +$383K 0.09% 102

Other funds holding AMGN

Stokes Family Office's AMGN Position: Q1 2026 in Review

Stokes Family Office reduced its Amgen (AMGN) stake by 10% in Q1 2026, selling an estimated $229K and leaving 5,766 shares worth $2.03M. The position accounts for 0.21% of the portfolio, ranked #94.

Stokes Family Office first reported a position in AMGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.1M in Q4 2025. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Stokes Family Office held 5,766 shares of Amgen worth $2.03M as of Q1 2026.
  • Stokes Family Office sold 642 Amgen shares in Q1 2026, an estimated $229K.
  • Amgen made up 0.21% of Stokes Family Office's portfolio in Q1 2026, its #94 holding.
  • Stokes Family Office first reported a position in Amgen in Q4 2019 and has held it in 26 quarters since.
  • Stokes Family Office's Amgen position peaked at $2.1M in Q4 2025.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.